These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 8325984

  • 1. Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide.
    Skorski T, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szcyzlik C, Chen ST, Lange B, Calabretta B.
    J Clin Invest; 1993 Jul; 92(1):194-202. PubMed ID: 8325984
    [Abstract] [Full Text] [Related]

  • 2. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T, Nieborowska-Skorska M, Wlodarski P, Perrotti D, Hoser G, Kawiak J, Majewski M, Christensen L, Iozzo RV, Calabretta B.
    J Natl Cancer Inst; 1997 Jan 15; 89(2):124-33. PubMed ID: 8998181
    [Abstract] [Full Text] [Related]

  • 3. [Autologous bone marrow transplantation for patients with chronic myelogenous leukemia after in vitro purging of the graft with bcr/abl antisense oligodeoxynucleotides].
    Sun J, Wu B, Liu Q, Feng R, Liu X, Meng F, Zhou S.
    Zhonghua Xue Ye Xue Za Zhi; 2000 Aug 15; 21(8):400-2. PubMed ID: 11877009
    [Abstract] [Full Text] [Related]

  • 4. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG, Joshi SS, Chan WC, Iversen PL, Jackson JD, Kessinger A, Pirruccello SJ, Sanger WG, Sharp JG, Verbik DJ.
    Leuk Lymphoma; 1995 Dec 15; 20(1-2):67-76. PubMed ID: 8750625
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Elimination of clonogenic Philadelphia-positive cells using BCR-ABL antisense oligodeoxynucleotides.
    de Fabritiis P, Amadori S, Calabretta B, Mandelli F.
    Bone Marrow Transplant; 1993 Sep 15; 12(3):261-5. PubMed ID: 8241986
    [Abstract] [Full Text] [Related]

  • 11. Interferon-alpha and bcr-abl antisense oligodeoxynucleotides in combination enhance the antileukemic effect and the adherence of CML progenitors to preformed stroma.
    Bellucci R, Sala R, De Propris MS, Cordone I, de Fabritiis P.
    Leuk Lymphoma; 1999 Nov 15; 35(5-6):471-81. PubMed ID: 10609784
    [Abstract] [Full Text] [Related]

  • 12. Oncogene-targeted antisense oligodeoxynucleotides combined with chemotherapy or immunotherapy: a new approach for tumor treatment?
    Nieborowska-Skórska M, Nakashima M, Ratajczak M, Steplewski Z, Calabretta B, Skórski T.
    Folia Histochem Cytobiol; 1994 Nov 15; 32(1):35-40. PubMed ID: 8026602
    [Abstract] [Full Text] [Related]

  • 13. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides.
    Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B.
    Science; 1991 Aug 02; 253(5019):562-5. PubMed ID: 1857987
    [Abstract] [Full Text] [Related]

  • 14. Amifostine improves the antileukemic therapeutic index of mafosfamide: implications for bone marrow purging.
    Douay L, Hu C, Giarratana MC, Bouchet S, Conlon J, Capizzi RL, Gorin NC.
    Blood; 1995 Oct 01; 86(7):2849-55. PubMed ID: 7670119
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligodeoxynucleotides: an in vitro study relevant to bone marrow purging.
    Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM.
    Proc Natl Acad Sci U S A; 1991 Mar 15; 88(6):2351-5. PubMed ID: 2006173
    [Abstract] [Full Text] [Related]

  • 17. Liposomal delivery of oligodeoxynucleotides.
    Tari A, Khodadadian M, Ellerson D, Deisseroth A, Lopez-Berestein G.
    Leuk Lymphoma; 1996 Mar 15; 21(1-2):93-7. PubMed ID: 8907275
    [Abstract] [Full Text] [Related]

  • 18. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E, Krahl R, Thalmeier K, Helbig W.
    Exp Hematol; 1995 Dec 15; 23(14):1649-54. PubMed ID: 8542960
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX, Ripoche J, Pigeonnier V, Jazwiec B, Pigneux A, Moreau JF, Reiffers J.
    Exp Hematol; 1995 Dec 15; 23(14):1606-11. PubMed ID: 8542954
    [Abstract] [Full Text] [Related]

  • 20. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF, Skorski T, van de Locht LT, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ.
    Leukemia; 1994 Jan 15; 8(1):129-40. PubMed ID: 8289478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.